Browsing Tag

Nasdaq:VINC

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models…

Eli Pacheco Dec 11, 2022 0

Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human…

Health

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate…

Eli Pacheco Aug 12, 2022 0

Continue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in…

Health

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152…

Eli Pacheco Jun 10, 2022 0

Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved…

Health

Vincerx Pharma Announces Poster Presentation at the American Association for Cancer…

Eli Pacheco Mar 9, 2022 0

PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer…

Health

Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of…

Eli Pacheco Dec 18, 2021 0

PALO ALTO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer…